NEW

DRUG

CONCEPTS

DEVELOPING A HEALTHIER FUTURE

“ENDECE is dedicated to the discovery and development of treatments that stop disease progression, restore function, and improve quality of life.”

James Yarger, Ph.D.

CEO

LATEST NEWS

ENDECE is preparing to take NDC-1308 into clinical studies. Our Dual Mechanism of Action (MOA) allows NDC-1308 to provide an anti-inflammatory environment and directly induce remyelination within the Central Nervous System (CNS). This dual MOA allows ENDECE to treat diseases such as Niemann-Pick disease type C, Neuromyelitis Optica Spectrum Disorder (NMOSD), Multiple Sclerosis (MS), and Alzheimer’s Disease.

NDC-1308  –  A DUAL MECHANISM OF ACTION

ANTI-INFLAMMATORY

NDC-1308 directly upregulates the Lipoprotein Lipase (LPL) gene and functional protein expression in the Central Nervous System (CNS), polarizing macrophages to the M2-like state (pro-repair, anti-inflammatory).

REMYELINATION

NDC-1308 directly upregulates key genes within Oligodendrocyte Progenitor Cells (OPCs) within the Central Nervous System (CNS) inducing the OPCs to differentiate into mature, myelinating oligodendrocytes.